ArticleFrontiers in oncology2026
Case Report: Leptomeningeal involvement in chronic lymphocytic leukemia patients with central nervous system infection: extramedullary manifestation or transmigration of leukocytes-how to treat this type of CLL?
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system (CNS) involvement by CLL is rare. We report a non-treated CLL patient with low-risk factors, but showed leptomeningeal involvement during/after neuroborreliosis and EBV meningitis. An 80-year-old woman with CLL in Binet stage A showed neurological syndromes and increased leukocytosis. The initial cerebrospinal fluid (CSF) revealed EBV-meningitis and neuroborreliosis, but no evidences for CNS involvement of CLL by flow cytometry and morphological/immunochemical assays. After antimicrobial treatment, neurological syndrome were significant improved. However, leukemic meningeal involvement was proved in following CSF analyses. Treatment with intrathecal chemotherapy and Bruton's tyrosine kinase inhibitor (BTKi) Zanubrutinib were performed. At the follow-up after 12 months, a complete remission was observed. Considering the case of our patient and previous reports, the question arises whether the detection of leukemic cells in the CSF of CLL patients with/after infectious meningitis (especially in neuroborreliosis) is an extramedullary manifestation or only a transmigration of clonal lymphocytes caused by the inflammation of the blood-brain barrier. The prophylaxis of CNS infections should be more seriously, since it may be associated with CLL leptomeningeal involvement. The need for an individualized therapy is certain, our case confirmed the efficacy of Zanubrutinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.